Catal­ent un­corks play in plas­mid DNA with buy­out of Bel­gian neigh­bor Del­phi, Mary­land ex­pan­sion launch

Dri­ven by boom­ing de­mand for cell and gene ther­a­py con­tract work, Catal­ent has signed some big checks in the past few years to se­cure its place as CD­MO No. 1 in that space. Now, the man­u­fac­tur­er is tar­get­ing plas­mid DNA pro­duc­tion to dive even deep­er — and it didn’t have to search long for a good place to start.

Catal­ent un­veiled plans to dive head­first in­to plas­mid DNA pro­duc­tion with the pur­chase of Bel­gian CD­MO Del­phi Ge­net­ics as well as the launch of man­u­fac­tur­ing ser­vices in that space at its Rockville, Mary­land fa­cil­i­ty, the com­pa­ny said Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER